BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18823779)

  • 1. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
    Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
    Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminomethylbenzimidazoles as potent ITK antagonists.
    Riether D; Zindell R; Kowalski JA; Cook BN; Bentzien J; Lombaert SD; Thomson D; Kugler SZ; Skow D; Martin LS; Raymond EL; Khine HH; O'Shea K; Woska JR; Jeanfavre D; Sellati R; Ralph KL; Ahlberg J; Labissiere G; Kashem MA; Pullen SS; Takahashi H
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1588-91. PubMed ID: 19246196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
    Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
    Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
    Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
    Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
    Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
    Ishikawa M; Nonoshita K; Ogino Y; Nagae Y; Tsukahara D; Hosaka H; Maruki H; Ohyama S; Yoshimoto R; Sasaki K; Nagata Y; Eiki J; Nishimura T
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4450-4. PubMed ID: 19540111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
    Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
    Das J; Furch JA; Liu C; Moquin RV; Lin J; Spergel SH; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Doweyko AM; Kamath A; Zhang H; Marathe P; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3706-12. PubMed ID: 16682193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
    Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.